Company: CERO
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001213900-25-079898
Chunk: 299

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 2
Chunk 299
---
 the Company sold an additional 938 shares of Series D Preferred Stock for gross cash proceeds of $750,400 in an additional
closing of the Fourth PIPE Financing.

On June 25, 2025, the Company
entered into an amendment (the “Amendment”) to the Fourth Securities Purchase Agreement pursuant to which the Company added
certain new institutional investors to the schedule of buyers in the Fourth Securities Purchase Agreement, to issue and sell to such investors,
in one or more closings shares of the Company’s Series D Preferred Stock. Also, on June 25, 2025, the Company sold an additional
2,315 shares of Series D Preferred Stock for gross cash proceeds of $1,852,000 in an additional closing of the Fourth PIPE Financing.

Item
3. Defaults Upon Senior Securities

None.

Item
4. Mine Safety Disclosures

Not
applicable.

Item
5. Other Information

From
time to time, our officers (as defined in Rule 16a–1(f)) and directors may enter into Rule 10b5-1 or non-Rule 10b5-1 trading arrangements
(as each such term is defined in Item 408 of Regulation S-K). None of our directors or “officers,” as defined in Rule 16a-1(f)
under the Securities Exchange Act of 1934, adopted or terminated a Rule 10b5-1 trading plan or arrangement or a non-Rule 10b5-1 trading
plan or arrangement, as defined in Item 408(c) of Regulation S-K, during the fiscal quarter covered by this report.

45

Item
6. Exhibits

The
following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.

    No.
     
    Description
    of Exhibit
  
    3.1
     
    Second
    Amended and Restated Certificate of Incorporation of CERo Therapeutics Holdings, Inc. (incorporated by reference to Exhibit 3.1 to
    the Current Report on Form 8-K/A filed by CERo Therapeutics Holdings, Inc. with the Securities and Exchange Commission on February
    27, 2024).

    3.2
     
    Second
    Amended and Restated Bylaws of CERo Therapeutics Holdings, Inc. (incorporated by reference to Exhibit 3.2 to the Current Report on
    Form 8